ab170190 - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues.
Isoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level).
Belongs to the PI3K p85 subunit family. Contains 1 Rho-GAP domain. Contains 2 SH2 domains. Contains 1 SH3 domain.
The SH3 domain mediates the binding to CBLB, and to HIV-1 Nef.
Polyubiquitinated in T-cells by CBLB; which does not promote proteasomal degradation but impairs association with CD28 and CD3Z upon T-cell activation. Phosphorylated. Dephosphorylated by PTPRJ.
Immunofuorescent analysis of HepG2 cells labeling PI 3 Kinase p85 with ab189403 at 1/100 dilution (green); Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.
Immunofuorescent analysis of HeLa cells labeling PI 3 Kinase p85 with ab189403 at 1/100 dilution (green); Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.
Yu N et al. Anti-Diabetic Effects of Jiang Tang Xiao Ke Granule via PI3K/Akt Signalling Pathway in Type 2 Diabetes KKAy Mice. PLoS One12:e0168980 (2017).
Read more (PubMed: 28045971) »
Huang G et al. Notoginsenoside R1 attenuates glucose-induced podocyte injury via the inhibition of apoptosis and the activation of autophagy through the PI3K/Akt/mTOR signaling pathway. Int J Mol Med39:559-568 (2017).
Read more (PubMed: 28112381) »